Qrativ, a joint venture of Mayo Clinic and Nference, seeks new treatments for rare diseases by coupling Mayo research with publicly available genomic data sets.
The company will pay nearly $2.1 million to the liquidating trust for the now-bankrupt HDL in order to resolve outstanding debt from a former joint lab venture.
Agilent will provide technology and training for the jointly-run lab, expanding on a 2011 deal to open a microarray technology center at Monash University Malaysia.
Horizon Discovery will use its experience with gene editing, immunology, and oncology to develop immunotherapies based on Centauri's antibody conjugate technology.
The Associated Press reports that an ethicist predicts that prenatal diagnosis and other advances will lead to more choices being available to prospective parents.
